tirzepatide lawsuit Eli Lilly sues Mochi Health and others for 'deceptive' marketing Zepbound Lawsuit [2026] | Gastrointestinal
Description
Semaglutide produces sustained weight reduction in most patients, but the rate of loss typically slows after 6 to 12 months as your body adapts
![tirzepatide lawsuit Eli Lilly sues Mochi Health and others for 'deceptive' marketing Zepbound Lawsuit [2026] | Gastrointestinal](https://www.torhoermanlaw.com/wp-content/uploads/2026/02/Zepbound-Lawsuit-768x384.jpg)
An important part of losing weight and maintaining that loss is establishing healthy habits during your journey
![tirzepatide lawsuit Eli Lilly sues Mochi Health and others for 'deceptive' marketing Zepbound Lawsuit [2026] | Gastrointestinal](https://media.cnn.com/api/v1/images/stellar/prod/gettyimages-2126120259-20250904110439644.jpg?c=original&q=w_860,c_fill)
For eyes with mild or moderate NPDR, early treatment with laser was not warranted, as the benefits in preventing vision loss did not outweigh the side effects (1)
![tirzepatide lawsuit Eli Lilly sues Mochi Health and others for 'deceptive' marketing Zepbound Lawsuit [2026] | Gastrointestinal](https://dlawgroup.com/wp-content/uploads/2025/05/Weight-Loss-Drugs-Ozempic-Mounjaro-Sued-Over-Stomach-Paralysis.jpg)
only one study had a follow-up greater than 1 year
Injectable Therapies for Diabetes: Ensuring Stability During Storage
![tirzepatide lawsuit Eli Lilly sues Mochi Health and others for 'deceptive' marketing Zepbound Lawsuit [2026] | Gastrointestinal](https://www.motleyrice.com/sites/default/files/styles/social_share/public/managed/cases/2025-01/diabetes-lawsuits-semaglutide.jpg.webp?itok=zBP8SV2v)
The absolute risk increase was larger for patients with a history of diabetic retinopathy at baseline (Ozempic 8.2%, placebo 5.2%), an increase of 2.8%